.png)
Denial rates have risen 33% since 2016. According to the Optum 2024 Denials Index, based on 124 million claims, the national average now sits at 12%, and 84% of those denials are potentially avoidable. Experian Health's 2025 State of Claims report found that 41% of providers now face denial rates above 10%, up from 30% just two years ago. For dermatology practices, where modifier complexity pushes denial rates above 14%, these numbers hit harder.
If you're trying to compare billing performance metrics across RCM vendors, the first thing you need to understand is that most vendor scorecards are designed to make the vendor look good, not to give you an honest picture of how your revenue cycle is performing. Working with 200+ dermatology practices across 42 states, we've reviewed hundreds of vendor scorecards and transition audits. The patterns repeat: numbers that look strong on paper but obscure real performance gaps once you dig into the methodology.
This guide breaks down the core metrics, shows how vendors manipulate them, and gives you a framework for making real comparisons.
Every RCM vendor will hand you a report showing strong numbers. Net collection rates in the high 90s. Clean claim rates above 95%. Days in A/R that look competitive. But when you line up two vendors' reports side by side, you're rarely comparing the same thing.
There is no universal requirement for how RCM vendors calculate or report performance metrics. HFMA developed 29 MAP Keys across five categories (patient access, pre-billing, claims, account resolution, and financial management) specifically to standardize revenue cycle measurement. But adoption is voluntary, and most vendors don't reference MAP Keys in their reporting unless a client asks.
Two vendors can report the same metric name with completely different underlying math. One vendor's "net collection rate" might exclude timely filing write-offs from the denominator while another includes them. Both show 96%, but one is genuinely collecting more of what's owed while the other has defined away its shortfalls. According to HFMA vendor management research, 50-65% of accounts handled by collection outsourcers fail to meet contract terms, SLAs, or regulations. That gap between reported and actual performance starts with how metrics are defined.
Six numbers matter most when comparing billing metrics across vendors. For each, you need to know not just the benchmark but how the number can be gamed.
NCR measures how much of what your practice is owed actually gets collected. Formula: total payments divided by allowable charges (charges minus contractual adjustments). Industry average sits at 90-95%. Best-in-class vendors hit 98% or higher, per MGMA benchmarks. For a deeper look at what these numbers mean for your specialty, see our breakdown of net collection rate benchmarks for dermatology.
How vendors game it: The biggest variable is what counts as a "contractual adjustment." Vendors inflate NCR by reclassifying write-offs (coding errors, timely filing failures) as contractual adjustments, shrinking the denominator. Reviewing NCR too early in the claim lifecycle also creates false strength because unaged claims haven't been denied yet. Ask whether your vendor separates contractual adjustments from non-contractual write-offs, and whether they report on a cash or accrual basis.
Optum's 2024 Denials Index, based on 124 million claims, found the national average at 12%, up from 9% in 2016. Experian Health's 2025 State of Claims report found 41% of providers now face denial rates above 10%, up from 30% in 2022. HFMA best practice is below 5%. MGMA's single-specialty aggregate is 8%.
How vendors game it: Some vendors only count hard denials while excluding soft denials (claims returned for additional information). A vendor reporting 4% that excludes soft denials might have a functional rate closer to 10%. Also check whether the rate is calculated by claim count or dollar amount, since high-value claim denials have outsized revenue impact.
Industry average runs 30-40 days. Best-in-class operations stay under 25. Anything above 50 signals serious follow-up or denial management problems.
How vendors game it: Writing off old claims prematurely drops the average because those claims exit the calculation. The number improves, but you've left collectible money behind. Vendors also lower this metric by prioritizing easy claims while complex ones sit. Ask for A/R aging broken down by 30-day buckets alongside the average. The breakdown tells a much more honest story.
Industry average ranges 85-95%. Above 95% is strong. Best-in-class hits 98%.
How vendors game it: "Clean" has no universal definition. Does it mean the claim passed the clearinghouse? Passed the payer's screening? Or was actually paid on first submission? A claim that clears the clearinghouse but gets denied by the payer could be counted as "clean" by vendors using the loosest definition. When a vendor says 97%, ask: does that mean clearinghouse acceptance or first-pass payment? Understanding each step of the revenue cycle helps you identify exactly where that definition might be masking a gap.
Target is above 90%. This metric has fewer standardized benchmarks and is often proxied through clean claim rate. It's more meaningful because it accounts for what happens after submission, not just whether the submission was error-free. Ask your vendor to define what "resolved" means and whether partial payments count.
Target is under 15-20% of total A/R. Best-performing operations keep this near zero. High percentages indicate denied claims aren't being worked systematically. If your vendor's 90+ day percentage dropped suddenly, ask whether the improvement came from collections or write-offs.
These six metrics work together, and we see this pattern frequently across the practices we work with: strong-looking numbers in one area often mask weakness in another. A high clean claim rate paired with a high denial rate, for example, usually means the "clean" definition isn't meaningful. That relationship between metrics is where the real story lives, and it's worth tracking all six together rather than fixating on any one number. For a focused look at the four metrics high-performing practices track, we've broken those down separately.
General benchmarks understate dermatology billing complexity significantly. Derm denial rates exceed 14%, compared to 5-10% for general specialties, and the gap comes from modifier complexity that generalist billing teams routinely miss. This is exactly why we focus exclusively on dermatology — the billing complexity demands specialty-specific expertise at every level.
Dermatology visits involve multiple procedures per session, each requiring correct coding and sequencing to avoid bundling errors and denials. Modifier 25 (significant, separately identifiable E/M service) is the most common derm modifier and the most common denial trigger when misapplied. Modifier 59 (distinct procedural service) triggers audits when overused and causes inappropriate bundling when omitted. CMS has been pushing toward X modifiers (XE, XS, XP, XU) as more specific replacements, adding another layer that generalist teams often handle poorly.
Modifier misapplication can significantly reduce per-claim reimbursement — in some cases by half or more — and can trigger fraud flags. Dermatology practices lose 5-15% of annual revenue to preventable coding errors. Mohs surgery pushes NCR targets above 97% for heavy practices, but documentation gaps and NCCI bundling rules make denials on these high-value claims costly. Multiple Procedure Payment Reductions (MPPR) require proper sequencing (100% for the highest RVU, 50% subsequent), and generalist vendors that don't understand this leave money behind on every multi-procedure visit.
Payer rules compound the difficulty. Cigna requires prior auth for biologics. Aetna has unique Mohs documentation requirements. Generic billing templates built for primary care don't account for these variations, and reworking a denied claim costs an average of $118. A practice running 14%+ denial rates and reworking hundreds of claims monthly feels that cost quickly.
Standardize definitions first. Ask each vendor for exact formulas for NCR, denial rate, days in A/R, and clean claim rate. Put them side by side and normalize against HFMA MAP Key definitions before comparing numbers.
Demand trailing 12-month data, not snapshots. Any single month can be misleading depending on payment cycles and seasonal volume. A vendor reluctant to share 12-month trends doesn't want you to see the full picture.
Break metrics down by payer. A practice might show 95% NCR overall while underperforming on commercial payers because strong Medicare collections pull the average up. Ask for payer-level reporting on your top five payers by volume.
In our experience, the practices that catch performance gaps early are the ones asking for metric relationships, not just individual numbers. High clean claim rate plus high denial rate means the "clean" definition isn't meaningful. Low days in A/R plus high write-offs suggests premature claim abandonment. Strong NCR plus rising 90+ day A/R means easy claims get collected while harder ones are neglected. These combinations tell you more than any single metric ever will.
Request write-off detail broken down by category: contractual adjustments, timely filing, coding errors, patient responsibility, uncollectable. This single report reveals more about billing quality than the entire scorecard. Score on transparency, not just performance. A vendor reporting slightly lower numbers with full methodology and trending data is often a better partner than one showing higher numbers with no context.
These patterns don't necessarily mean your vendor is failing. But they're worth investigating, and the questions they raise are worth asking.
Declining metrics over consecutive quarters without a clear, specific explanation. If a vendor can't point to a concrete cause — a payer policy change, a staffing transition, a claims system migration — vague answers or external blame are themselves a signal.
Below-benchmark numbers without acknowledgment. If your denial rate is above 10% and your vendor's report doesn't flag it, it's worth asking why. Optum's data shows 84% of denials are avoidable. A billing partner invested in your performance should be actively working that number down and communicating the plan.
Reluctance to share methodology. How NCR is calculated should be explainable in two sentences. If the answer is vague or overly complicated, the formula may be structured to flatter performance.
No proactive communication. In derm, where payer rules change frequently and modifier complexity creates constant risk, reactive management costs you money every month. If you're learning about denied claims or payer policy changes after they've already impacted your revenue, that's a conversation worth having with your vendor.
High write-off rates paired with low days in A/R. This combination often means cash flow numbers are improving because collectible claims are being abandoned. Compare write-offs as a percentage of net patient revenue against the 2-3% benchmark for well-performing practices. If you're seeing it, it's worth asking what percentage of those write-offs were non-contractual, and what was the rework attempt rate before they were written off.
Q: What is the most important billing metric when comparing RCM vendors?
A: Net collection rate, because it directly measures how much of what your practice is owed gets collected. But NCR alone is misleading without knowing the vendor's formula. Always ask what counts as a contractual adjustment versus a write-off, and compare the methodology against HFMA MAP Key definitions.
Q: How do I catch my vendor cherry-picking metrics?
A: Ask for trailing 12-month data, payer-level breakdowns, and write-off detail by category. If the vendor pushes back or claims the data isn't available, they're presenting a curated version of their performance. The reluctance to share is often more telling than the numbers themselves.
Q: What benchmarks should a dermatology practice specifically hit?
A: NCR above 97%, denial rate below 8% (the MGMA single-specialty aggregate), days in A/R under 30, and clean claim rate above 95% using first-pass payer payment as the definition. These targets are harder to hit than general-practice benchmarks because of modifier complexity and multi-procedure visits.
Q: What should I do if my vendor won't share their calculation methodology?
A: Start by putting the request in writing: ask for exact formulas for NCR, denial rate, clean claim rate, and days in A/R, along with what's included and excluded from each calculation. If you get resistance, ask whether they'd be willing to map their reporting to HFMA MAP Key definitions. A vendor confident in their numbers should welcome the transparency. If they can't or won't provide it, that tells you something about how those numbers were built.
Q: What questions should I ask my RCM vendor about their reported metrics?
A: Five questions that matter most: (1) What's your exact NCR formula, and what do you classify as a contractual adjustment? (2) Does your clean claim rate measure clearinghouse acceptance or first-pass payment? (3) What percentage of write-offs are non-contractual? (4) Can you provide payer-level breakdowns? (5) How does your reporting align with HFMA MAP Key definitions?
The gap between reported vendor metrics and actual performance exists because the industry lacks enforceable standards for how vendors measure and present their work. Standardize definitions, demand granular data, and evaluate relationships between metrics rather than any single number in isolation.
For dermatology practices, this goes further. Modifier complexity, multi-procedure visits, and payer-specific documentation rules mean your vendor needs to do more than report clean numbers — they need to demonstrate they understand why dermatology billing requires specialty expertise and how they're applying it to your claims. Insisting on specialty-specific benchmarks and modifier-level reporting separates vendors who understand derm billing from those who treat it as one more specialty in a generalist portfolio.
